Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
about
Telomere and Telomerase Therapeutics in CancerTelomerase as a Cancer Target. Development of New MoleculesIdentification of the Key Fields and Their Key Technical Points of Oncology by Patent Analysis.Belagenpumatucel-L for the treatment of non-small cell lung cancer.MYCN-targeting vaccines and immunotherapeutics.
P2860
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
@ast
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
@en
type
label
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
@ast
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
@en
prefLabel
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
@ast
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.
@en
P2093
P2860
P50
P1476
Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one
@en
P2093
Alessia Parodi
Andrea Guastalla
Augusto Tagliamacco
Francesca Ferrera
Francesca Kalli
Maria Giuseppina Lamperti
Rosa Lavieri
P2860
P304
P356
10.1080/21645515.2015.1012032
P577
2015-01-01T00:00:00Z